Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial.
| Title: | Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial. |
|---|---|
| Authors: | Palevičiūtė E; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu-2, 08661, Vilnius, Lithuania. egle.paleviciute@santa.lt.; Čelutkienė J; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu-2, 08661, Vilnius, Lithuania.; Šimbelytė T; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu-2, 08661, Vilnius, Lithuania.; Gumbienė L; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu-2, 08661, Vilnius, Lithuania.; Jurevičienė E; Faculty of Medicine, Vilnius University, Vilnius, Lithuania.; Zakarkaitė D; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu-2, 08661, Vilnius, Lithuania.; Čėsna S; Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariskiu-2, 08661, Vilnius, Lithuania.; Eichstaedt CA; Centre for Pulmonary Hypertension, German Center for Lung Research (DZL), Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany.; Laboratory for Molecular Genetic Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.; Benjamin N; Centre for Pulmonary Hypertension, German Center for Lung Research (DZL), Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany.; Grünig E; Centre for Pulmonary Hypertension, German Center for Lung Research (DZL), Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany. |
| Source: | Trials [Trials] 2023 Apr 19; Vol. 24 (1), pp. 281. Date of Electronic Publication: 2023 Apr 19. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BioMed Central, 2006- |
| MeSH Terms: | Heart Failure*/complications ; Heart Failure*/diagnosis ; Heart Failure*/therapy ; Hypertension, Pulmonary*/diagnosis ; Hypertension, Pulmonary*/therapy; Humans ; Stroke Volume ; Ventricular Function, Left ; Quality of Life ; Treatment Outcome ; Exercise ; Biomarkers ; Exercise Tolerance ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic |
| Abstract: | Background: Left heart failure (HF) is characterized by an elevation in left-sided filling pressures, causing symptoms of dyspnea, impairing exercise capacity, and leading to pulmonary venous congestion and secondary pulmonary hypertension (PH). There is an increased incidence of PH associated with left heart disease, particularly with heart failure with preserved ejection fraction (HFpEF-PH). Treatment possibilities in HFpEF-PH are non-specific and very limited, thus additional pharmacological and non-pharmacological therapeutic strategies are needed. Various types of exercise-based rehabilitation programs have been shown to improve exercise capacity and quality of life (QoL) of HF and PH patients. However, no study focused on exercise training in the population of HFpEF-PH. This study is designed to investigate whether a standardized low-intensity exercise and respiratory training program is safe and may improve exercise capacity, QoL, hemodynamics, diastolic function, and biomarkers in patients with HFpEF-PH.; Methods: A total of 90 stable patients with HFpEF-PH (World Health Organization functional class II-IV) will be randomized (1:1) to receive a 15-week specialized low-intensity rehabilitation program, including exercise and respiratory therapy and mental gait training, with an in-hospital start, or standard care alone. The primary endpoint of the study is a change in 6-min walk test distance; secondary endpoints are changes in peak exercise oxygen uptake, QoL, echocardiographic parameters, prognostic biomarkers, and safety parameters.; Discussion: To date, no study has investigated the safety and efficacy of exercising specifically in the HFpEF-PH population. We believe that a randomized controlled multicenter trial, which protocol we are sharing in this article, will add important knowledge about the potential utility of a specialized low-intensity exercise and respiratory training program for HFpEF-PH and will be valuable in finding optimal treatment strategies for these patients.; Trial Registration: ClinicalTrials.gov NCT05464238. July 19, 2022.; (© 2023. The Author(s).) |
| References: | Clin Res Cardiol. 2015 Mar;104(3):197-207. (PMID: 25479818); JACC Heart Fail. 2018 Aug;6(8):665-675. (PMID: 29803552); Eur Heart J. 2018 Aug 7;39(30):2825-2835. (PMID: 29947750); J Am Coll Cardiol. 2019 Apr 2;73(12):1430-1443. (PMID: 30922474); J Am Coll Cardiol. 2009 Mar 31;53(13):1119-26. (PMID: 19324256); JAMA Cardiol. 2018 Apr 1;3(4):298-306. (PMID: 29541759); Acta Psychiatr Scand. 1983 Jun;67(6):361-70. (PMID: 6880820); Eur Heart J. 2009 Feb;30(4):394-403. (PMID: 19155250); Heart Fail Rev. 2023 Jan;28(1):193-206. (PMID: 35831689); JACC Heart Fail. 2019 Aug;7(8):691-705. (PMID: 31302050); Eur Heart J. 2016 Mar 21;37(12):942-54. (PMID: 26508169); Am J Respir Crit Care Med. 2015 Nov 15;192(10):1234-46. (PMID: 26181215); Lancet Respir Med. 2016 Apr;4(4):306-22. (PMID: 26975810); Respiration. 2021;100(5):369-378. (PMID: 33765679); Int J Cardiol. 2015 Jan 15;178:142-6. (PMID: 25464238); Curr Atheroscler Rep. 2019 Nov 9;21(11):45. (PMID: 31707525); Circulation. 2006 Oct 3;114(14):1482-9. (PMID: 16982941); Am J Respir Crit Care Med. 2003 May 1;167(9):1287. (PMID: 12714344); J Appl Physiol (1985). 2015 Sep 15;119(6):726-33. (PMID: 25749444); Am J Cardiol. 2010 Jul 15;106(2):284-6. (PMID: 20599017); J Am Coll Cardiol. 2001 Jan;37(1):183-8. (PMID: 11153735); J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8. (PMID: 24355634); Heart Fail Rev. 2020 Mar;25(2):305-319. (PMID: 31364028); JACC Heart Fail. 2013 Aug;1(4):290-299. (PMID: 24621932); Eur Respir J. 2019 Feb 28;53(2):. (PMID: 30578391); Eur Respir J. 2009 Sep;34(3):669-75. (PMID: 19720810); Eur Heart J. 2018 Aug 7;39(30):2810-2821. (PMID: 29788047); Heart Fail Rev. 2019 Jul;24(4):535-547. (PMID: 31032533); Int J Cardiol. 2012 Dec 15;162(1):6-13. (PMID: 22664368); Med Care. 1993 Mar;31(3):247-63. (PMID: 8450681); Cochrane Database Syst Rev. 2017 Jan 19;1:CD011285. (PMID: 28099988); Eur Heart J. 2016 Jan 1;37(1):35-44. (PMID: 26231884); BMC Pulm Med. 2015 Apr 22;15:40. (PMID: 25896259); Lancet Respir Med. 2020 Sep;8(9):873-884. (PMID: 32730752); Int J Cardiol. 2018 Dec 1;272S:53-62. (PMID: 30527996); J Am Heart Assoc. 2021 Jan 19;10(2):e019949. (PMID: 33399006); Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):177. (PMID: 26837729); Eur Respir J. 2012 Jul;40(1):84-92. (PMID: 22323570); Respiration. 2011;81(5):394-401. (PMID: 21311162); Eur Heart J. 2021 Jun 14;42(23):2284-2295. (PMID: 33232470); Eur J Heart Fail. 2018 Dec;20(12):1735-1743. (PMID: 30255969); BMJ. 2013 Jan 08;346:e7586. (PMID: 23303884); Open Heart. 2015 Jan 28;2(1):e000163. (PMID: 25685361); J Am Coll Cardiol. 2020 Sep 1;76(9):1102-1111. (PMID: 32854845); Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545974); PLoS One. 2012;7(7):e41603. (PMID: 22848542); Circ Heart Fail. 2015 Jan;8(1):33-40. (PMID: 25399909); N Engl J Med. 2021 Oct 14;385(16):1451-1461. (PMID: 34449189); Eur Heart J. 2021 Sep 21;42(36):3599-3726. (PMID: 34447992); Prog Cardiovasc Dis. 2020 Sep - Oct;63(5):570-584. (PMID: 32387101); Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545971); JAMA. 2009 Apr 8;301(14):1451-9. (PMID: 19351942); Eur Respir J. 2018 Apr 4;51(4):. (PMID: 29439019); Monaldi Arch Chest Dis. 2016 Oct 14;86(1-2):759. (PMID: 27748473) |
| Contributed Indexing: | Keywords: Exercise training; Heart failure with preserved ejection fraction; Pulmonary hypertension; Randomized controlled trial; Study protocol |
| Molecular Sequence: | ClinicalTrials.gov NCT05464238 |
| Substance Nomenclature: | 0 (Biomarkers) |
| Entry Date(s): | Date Created: 20230419 Date Completed: 20230420 Latest Revision: 20240917 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10114476 |
| DOI: | 10.1186/s13063-023-07297-x |
| PMID: | 37072812 |
| Database: | MEDLINE |
Clinical Trial Protocol; Journal Article